Contents 1 min reading
Claim and source comparison
Vinpocetine: dementia research and the FDA pregnancy safety warning.
· Bounded source comparison; not a complete clinical review or independent medical endorsement.
Systematic review / meta-analysis
The 2003 Cochrane review analysed available data for 583 people with dementia across 3 studies. Some measures differed, but the authors found the evidence insufficient to support clinical use.
Diagnostic criteria varied, adverse effects were reported inconsistently and intention-to-treat data were unavailable. These results cannot be generalized to healthy people.
Source 7 · Abstract read
Official safety summary
In 2019 the FDA advised pregnant people and those who could become pregnant to avoid vinpocetine because of possible miscarriage or harm to fetal development.
This is a reproductive safety warning. The tentative US assessment of supplement status announced in 2016 is a separate matter.
Source 6 · Official summary read
Correction · 2026-11-11: Removed generalized dose, half-life and mechanism claims. Linked the dementia review and pregnancy warning to their sources.
Important Note
FDA’s 2019 warning advises pregnant women and women who could become pregnant not to take vinpocetine because of miscarriage or fetal-development risks. Its 2016 dietary-supplement definition position is a separate issue. Anticoagulants, blood-pressure medicines and bleeding risk need medical review.
What is Vinpocetine?
Vinpocetine is a synthetic ethyl ester of apovincamine.
Mechanism of Effect
Clinical Evidence
Hindmarch et al. (1991) studied 203 patients with organic psychosyndromes, not healthy older adults, for 16 weeks with placebo or vinpocetine 3×10/3×20 mg daily. Subhan and Hindmarch (1985) yielded short-term, limited test findings in 12 healthy women, not evidence of general cognitive enhancement.
Dose information and research limits
Dose information and research limits
This dose information describes research or product context; it is not a personal prescription, established safe upper limit or efficacy guarantee for healthy people. Extracts and different formulations should not be treated as equivalent milligram for milligram.
Sources
- Hindmarch I, et al. (1991). Efficacy and tolerance of vinpocetine in ambulant patients suffering from mild to moderate organic psychosyndromes. International Clinical Psychopharmacology, 6(1), 31–43. PubMed · PMID 2071888
- Subhan Z & Hindmarch I (1985). Psychopharmacological effects of vinpocetine in normal healthy volunteers. European Journal of Clinical Pharmacology, 28(5), 567–571. PubMed · PMID 3899677
- Bereczki D & Fekete I (2008). Vinpocetine for acute ischaemic stroke. Cochrane Database of Systematic Reviews, (1), CD000480. PubMed · PMID 18253980
- Valikovics A (2007). Investigation of the effect of vinpocetine on cerebral blood flow and cognitive functions. Ideggyogy Sz, 60(7–8), 301–310. PubMed · PMID 17713111
- Kemény V, et al. (2005). Acute and chronic effects of vinpocetine on cerebral hemodynamics and neuropsychological performance in multi-infarct patients. Journal of Clinical Pharmacology, 45(9), 1048–54. https://doi.org/10.1177/0091270005279363 PubMed · PMID 16100299
- US Food and Drug Administration. Vinpocetine in Dietary Supplements. https://www.fda.gov/food/information-select-dietary-supplement-ingredients-and-other-substances/vinpocetine-dietary-supplements US Food and Drug Administration
- Szatmari SZ, Whitehouse PJ. (2003). Vinpocetine for cognitive impairment and dementia. Cochrane Database of Systematic Reviews, (1), CD003119. PubMed · PMID 12535455
Link verification checks the identity of the publication; it does not constitute independent expert review of clinical claims. Our evidence and source methodology · Source directory
Frequently Asked Questions
Vinpocetine is a vasoactive synthetic compound studied in older patient trials. Rapid focus or memory enhancement in healthy people is not established; a blood-flow mechanism alone does not establish cognitive benefit.
Hindmarch et al. (1991) studied 203 patients with organic psychosyndromes, not healthy older adults, for 16 weeks with placebo or vinpocetine 3×10/3×20 mg daily. Subhan and Hindmarch (1985) yielded short-term, limited test findings in 12 healthy women, not evidence of general cognitive enhancement.
FDA’s 2019 warning advises pregnant women and women who could become pregnant not to take vinpocetine because of miscarriage or fetal-development risks. Its 2016 dietary-supplement definition position is a separate issue. Anticoagulants, blood-pressure medicines and bleeding risk need medical review.
Sale and import status in Türkiye must be checked for the specific product. Verify supplement approval in the Ministry of Agriculture and Forestry GGBS list, and medicine authorization and conditions of use in TİTCK records. Online availability does not establish approval or unrestricted personal import; current Ministry of Trade conditions apply to postal and express shipments.
No established timeframe